Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Kamada Ltd. (KMDA : NSDQ)

• Company Description    Kamada Ltd. is a biopharmaceutical company. It develops, produces and markets therapeutics based on chromatographic purification technology. The company offers bio-therapeutics for specialty proteins, specific immunoglobulins and other prescription medicines. Kamada Ltd. is headquartered in Ness Ziona, Israel. Number of Employees: 462

• Price / Volume Information    Yesterday's Closing Price: $8.54 Daily Weekly Monthly 20 Day Moving Average: 182,180 shares Shares Outstanding: 57.51 (millions) Market Capitalization: $491.09 (millions) Beta: 0.88 52 Week High: $9.35 52 Week Low: $6.50 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 19.61% 20.14% 12 Week 14.48% 12.04% Year To Date 20.96% 7.28%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 2 HOLTZMAN ST. SCIENCE PARK - REHOVOT,L3 7670402 ISR ph: 972-8940-6472 fax: 972-8940-6473 ir@kamada.com http://www.kamada.com

• General Corporate Information    Officers Amir London - Chief Executive Officer Lilach Asher-Topilsky - Chair of the Board of Directors Eran Nir - Chief Operating Officer Chaime Orlev - Chief Financial Officer Uri Botzer - Director Peer Information Kamada Ltd. (CORR.) Kamada Ltd. (RSPI) Kamada Ltd. (CGXP) Kamada Ltd. (BGEN) Kamada Ltd. (GTBP) Kamada Ltd. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: M6240T109 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/26 Next Expected EPS Date: 11/09/26 Share - Related Items Shares Outstanding: 57.51 Most Recent Split Date: (:1) Beta: 0.88 Market Capitalization: $491.09 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 1.49% Current Fiscal Quarter EPS Consensus Estimate: $0.14 Indicated Annual Dividend: $0.13 Current Fiscal Year EPS Consensus Estimate: $0.49 Payout Ratio: 0.49 Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: 0.43 Estmated Long-Term EPS Growth Rate: 25.00% Last Dividend Paid: 08/27/2026 - $0.13 Next EPS Report Date: 11/09/26

• Fundamental Ratios P/E Current FY Estimate: 17.43 Trailing 12 Months: 22.47 PEG Ratio: 0.70 Price Ratios Price/Book: 1.82 Price/Cash Flow: 13.98 Price / Sales: 2.56 EPS Growth vs. Year Ago Period: 23.08% vs. Previous Quarter: 128.57% Sales Growth vs. Year Ago Period: 22.72% vs. Previous Quarter: 21.40% ROE 06/30/26 - 8.37 03/31/26 - 7.73 12/31/25 - 7.72 ROA 06/30/26 - 5.85 03/31/26 - 5.41 12/31/25 - 5.39 Current Ratio 06/30/26 - 4.06 03/31/26 - 3.33 12/31/25 - 4.07 Quick Ratio 06/30/26 - 2.29 03/31/26 - 1.90 12/31/25 - 2.28 Operating Margin 06/30/26 - 11.60 03/31/26 - 11.21 12/31/25 - 11.19 Net Margin 06/30/26 - 11.60 03/31/26 - 11.21 12/31/25 - 11.19 Pre-Tax Margin 06/30/26 - 13.91 03/31/26 - 12.24 12/31/25 - 13.00 Book Value 06/30/26 - 4.69 03/31/26 - 4.51 12/31/25 - 4.68 Inventory Turnover 06/30/26 - 1.33 03/31/26 - 1.27 12/31/25 - 1.26 Debt-to-Equity 06/30/26 - 0.00 03/31/26 - 0.00 12/31/25 - 0.00 Debt-to-Capital 06/30/26 - 0.00 03/31/26 - 0.00 12/31/25 - 0.00

Powered by Zacks Investment Research ©